Biotech RadarJobs updated

COMPANY

AnchorDx

anchordx.com ↗

Profile checked Oct 10, 2026

Keywords: Pulmonary Nodules Urothelial Carcinoma Bladder Cancer Upper Tract Urothelial Carcinoma

4Trials (company is sponsor)

Timeline

  1. Trial start —: Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection source ↗
  2. Trial start —: A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers source ↗
  3. Trial start —: Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma source ↗
  4. Trial start —: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules source ↗

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT04314245Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial CarcinomaNot listedCompletedAug 1, 2019Nov 30, 2021 (actual)
NCT04462185A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive BiomarkersNot listedUnknown status (ClinicalTrials.gov)Jul 1, 20202024-06 (estimated)
NCT04948528Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma DetectionNot listedUnknown status (ClinicalTrials.gov)Sep 1, 2020Jun 25, 2023 (estimated)
NCT03651986Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary NodulesNot listedUnknown status (ClinicalTrials.gov)Nov 26, 20182024-09 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback